ChitogenX (CHGX) AI Stock Analysis

• Market Cap: C$415.65K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 83,129,520
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 24 Underperform
• Price Target: ―

ChitogenX's overall stock score reflects significant financial instability with no revenue, high debt levels, and negative cash flows, coupled with technical indicators pointing towards bearish trends. The lack of earnings or dividends makes the stock less appealing from a valuation perspective.

ChitogenX Business Overview & Revenue Model

Company Description

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.

How the Company Makes Money

ChitogenX makes money through the development, licensing, and sales of its proprietary medical products and technologies. The company's primary revenue streams include direct sales of its chitosan-based products to healthcare providers and institutions, as well as licensing agreements with other medical device and pharmaceutical companies that incorporate ChitogenX's technology into their own product offerings. Additionally, ChitogenX may engage in strategic partnerships and collaborations to expand its market reach and enhance its product pipeline, further contributing to its earnings.

ChitogenX Financial Statement Overview

Summary

ChitogenX faces significant financial challenges with no revenue generation, high levels of debt, and negative cash flows. The company shows a pattern of financial instability, with profitability and liquidity concerns that need to be addressed to ensure sustainable operations.

Income Statement

ChitogenX has reported negative gross profit and net income with no revenue, indicating that the company is not currently generating sales but incurring costs. The lack of revenue growth and negative margins highlight significant profitability challenges.

Balance Sheet

The balance sheet shows negative stockholders' equity and a high debt-to-equity ratio, both of which suggest financial instability and potential risks in leveraging. The equity ratio is negative due to negative equity, indicating that the company is financed more by debt than equity.

Cash Flow

ChitogenX's cash flow statements reveal ongoing negative operating and free cash flows, indicating that the company is consuming more cash than it generates. The cash flow from operations is insufficient to cover net income, suggesting potential liquidity challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-42.00K	-59.00K	-69.00K	-89.00K	-119.00K
EBITDA	-670.00K	-4.75M	-3.44M	-2.54M	-2.06M
Net Income	-1.55M	-6.23M	-4.92M	-3.77M	-2.49M
Balance Sheet
Total Assets	534.00K	738.00K	1.12M	3.28M	1.29M
Cash, Cash Equivalents and Short-Term Investments	35.00K	108.00K	313.00K	2.38M	302.00K
Total Debt	3.88M	5.56M	5.71M	4.62M	2.61M
Total Liabilities	6.71M	10.58M	8.23M	5.08M	3.69M
Stockholders Equity	-6.18M	-9.84M	-7.10M	-1.80M	-2.40M
Cash Flow
Free Cash Flow	-1.01M	-3.20M	-3.25M	-2.98M	-1.59M
Operating Cash Flow	-1.01M	-3.20M	-3.22M	-2.98M	-1.59M
Investing Cash Flow	0.00	0.00	-33.00K	-3.00K	0.00
Financing Cash Flow	937.00K	2.94M	1.16M	5.05M	1.37M

ChitogenX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CHGX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 33.33 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CHGX.

ChitogenX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	53 Neutral	C$49.08M	23.83	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	49 Neutral	C$34.05M	-15.19	-8.01%	―	-26.81%	-161.24%
HEM	41 Neutral	C$16.02M	-2.92	―	―	―	-24.89%
KNE	41 Neutral	C$6.90M	-3.11	―	―	―	―
CHGX	24 Underperform	C$415.65K	-0.53	21.10%	―	―	―